Literature DB >> 8891159

In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis.

L Mulazimoglu1, S D Drenning, V L Yu.   

Abstract

Two oxazolidinones (U100592 and U100766), trovafloxacin, and a streptogramin combination (dalfopristin-quinupristin) were highly active in vitro against Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-resistant strains. Trovafloxacin was more active than ciprofloxacin. Time-kill synergy studies demonstrated indifference for the oxazolidinones combined with vancomycin and rifampin against methicillin-resistant staphylococci. Spontaneous resistance was observed with all agents.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8891159      PMCID： PMC163549     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  In vitro activity of the new fluoroquinolone CP-99,219.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

2.  In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.

Authors:  G E Zurenko; B H Yagi; R D Schaadt; J W Allison; J O Kilburn; S E Glickman; D K Hutchinson; M R Barbachyn; S J Brickner
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

3.  Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center.

Authors:  D P Levine; R D Cushing; J Jui; W J Brown
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

4.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

5.  Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.

Authors:  J S Daly; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1988-06       Impact factor: 5.790

6.  Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.

Authors:  L Hirschhorn; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191
  6 in total
  12 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Assessment of inhibitory potency of antibiotics by MRI: apparent T2 as a marker of cell growth.

Authors:  Verena Hoerr; Kerstin Hoffmann; Curd Schollmayer; Ulrike Holzgrabe; Axel Haase; Peter Jakob; Cornelius Faber
Journal:  MAGMA       Date:  2006-11-10       Impact factor: 2.310

3.  Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients.

Authors:  C A Johnson; C A Taylor; S W Zimmerman; W E Bridson; P Chevalier; O Pasquier; R I Baybutt
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

5.  Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.

Authors:  M J Rybak; D M Cappelletty; T Moldovan; J R Aeschlimann; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.

Authors:  Andrew E Simor; Mark Loeb
Journal:  Can J Infect Dis       Date:  2004-01

7.  Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis.

Authors:  Charlene F Dailey; Paul J Pagano; Lewis V Buchanan; Jennifer A Paquette; Joseph V Haas; John K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus.

Authors:  Patrick Grohs; Marie-Dominique Kitzis; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 9.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 10.  Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Authors:  J C Pechère; T D Gootz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.